Liontrust Investment Partners LLP Reduces Stake in TransMedics Group, Inc. $TMDX

Liontrust Investment Partners LLP lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 5.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 523,748 shares of the company’s stock after selling 30,609 shares during the period. Liontrust Investment Partners LLP owned 1.54% of TransMedics Group worth $70,187,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in TransMedics Group by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company’s stock worth $154,000 after purchasing an additional 278 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 2.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company’s stock valued at $20,478,000 after buying an additional 6,934 shares during the period. Nuveen LLC acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $5,927,000. HighTower Advisors LLC increased its holdings in shares of TransMedics Group by 137.7% during the 1st quarter. HighTower Advisors LLC now owns 18,257 shares of the company’s stock worth $1,228,000 after buying an additional 10,575 shares during the last quarter. Finally, Sit Investment Associates Inc. raised its position in shares of TransMedics Group by 8.8% during the 1st quarter. Sit Investment Associates Inc. now owns 7,380 shares of the company’s stock valued at $497,000 after buying an additional 600 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $126.79 on Friday. The stock’s 50-day moving average price is $126.72 and its 200 day moving average price is $123.09. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $156.00. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of 51.33 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 earnings per share. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. This represents a 59.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,062 shares of company stock valued at $1,797,634 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on TMDX. Canaccord Genuity Group increased their price objective on TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Evercore ISI initiated coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price on the stock. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $136.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.